Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a license agreement regarding Nxera technology used to help design Centessa’s novel orexin receptor 2 (OX2R) agonist, ORX750.
- Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a license agreement regarding Nxera technology used to help design Centessa’s novel orexin receptor 2 (OX2R) agonist, ORX750.
- The milestone was achieved with clearance of the ORX750 Investigational New Drug application and progression of ORX750 into a Phase 1 clinical trial.
- ORX750 is an investigational, orally administered, highly potent and selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 (NT1), with potential applicability to narcolepsy type 2 (NT2), idiopathic hypersomnia, and other sleep-wake disorders with normal orexin levels.